Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Investor Newsletters
Corporate Governance
Shareholder Services
Media Centre
Overview
Latest News
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Latest News
Overview
Latest News
Video
Coverage
Latest News
Filter by Year:
2022
2021
2020
2-Sep-2021
Evt801 Phase I Study Receives Full Regulatory Approval
30-Jul-2021
Quarterly Activities Report And Appendix 4c
21-Jul-2021
Kazia Calls For Increased Focus On Brain Cancer Research This Gbm Awareness Day
30-Jun-2021
Kazia Provides Progress Update On Paxalisib And Evt801 Clinical Programs
24-Jun-2021
Manufacturing Patents Granted For Paxalisib In Key Territories; Extend Effective Patent Protection To 2036
15-Jun-2021
Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma
7-Jun-2021
Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient
19-Apr-2021
Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se
29-Mar-2021
Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company
1-Mar-2021
Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab
Previous
1
2
3
4
5
Next
